Literature DB >> 8104685

Soluble intercellular adhesion molecule 1 (sICAM-1) and malignant melanoma.

J Viac1, A Gueniche, M Faure, A Claudy.   

Abstract

A soluble form of the intercellular adhesion molecule-1 (sICAM-1) has been reported to be elevated in malignant melanoma. We have studied the expression of sICAM-1 by ELISAs in a series of 85 consecutive sera derived from patients with primary or metastatic melanomas in comparison with control patients and patients with diffuse acute eczema and psoriasis. Our results showed elevated sICAM-1 concentrations in patients with malignant melanoma but also in patients with extensive inflammatory dermatoses. The diagnostic potential of sICAM-1 in malignant melanoma appears to be limited. Further studies are needed to determine whether increased values of sICAM-1 in primary melanomas may predict a progression of the disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104685     DOI: 10.1016/0304-3835(93)90128-v

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Down regulation of endothelial adhesion molecules in node positive breast cancer: possible failure of host defence mechanism.

Authors:  Maya Madhavan; Priya Srinivas; Elizabeth Abraham; Iqbal Ahmed; N R Vijayalekshmi; Prabha Balaram
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

2.  Serum levels of the soluble adhesion molecules in patients with malignant melanoma.

Authors:  V Yasasever; F Tas; D Duranyildiz; H Camlica; S Kurul; N Dalay
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancer.

Authors:  G Velikova; R E Banks; A Gearing; I Hemingway; M A Forbes; S R Preston; M Jones; J Wyatt; K Miller; U Ward; J Al-Maskatti; S M Singh; N S Ambrose; J N Primrose; P J Selby
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.